Clinical trial · Interventional
Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration
NCT00280514CI-TRIAL-00003739completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Penetration of cefpirome and moxifloaxacin into abscess fluid of humans will be tested. Patients with an abscess scheduled for drainage will receive study drugs (single or multiple dose), pus samples and plasma samples will be collected and analyzed by High pressure liquid chromatography (HPLC). Pharmacokinetics of the study drugs in pus and plasma will be determined using a pharmacokinetic model.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abscess | — | UNRESOLVED | — |
| Cysts | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cefpirome and moxifloxacin administration | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (6)
- measure
- AUC
- measure
- AUC0-12/24h
- measure
- Cmax
- measure
- Tmax
- measure
- t1/2ß
- measure
- Cav(ss)
Secondary outcomes (2)
- measure
- ratios of AUC and Cav(ss) to MIC
- measure
- T>MIC
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Female or male, aged between 18 and 90 years. * Written informed consent. * Abscess formation or abdominal cyst scheduled to drainage. * Plasma creatinine \<1.5 mg/dL Exclusion Criteria: * Pregnancy or lactation. * Hemodialysis or hemofiltration * Allergy or hypersensitivity against study drugs * Massive edemata or hypernatremia * Reduced liver function (Child-Pugh A, B, C) * Relevant prolongation of QT-interval * CNS-diseases which predispose for cramps
References
Publications (1)
- BACKGROUNDSauermann R, Karch R, Langenberger H, Kettenbach J, Mayer-Helm B, Petsch M, Wagner C, Sautner T, Gattringer R, Karanikas G, Joukhadar C. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother. 2005 Nov;49(11):4448-54. doi: 10.1128/AAC.49.11.4448-4454.2005. PMID 16251282